[Federal Register Volume 77, Number 78 (Monday, April 23, 2012)]
[Notices]
[Pages 24209-24210]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2012-9720]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Centers for Disease Control and Prevention

[60Day-12-12II]


Proposed Data Collections Submitted for Public Comment and 
Recommendations

    In compliance with the requirement of Section 3506(c)(2)(A) of the 
Paperwork Reduction Act of 1995 for opportunity for public comment on 
proposed data collection projects, the Centers for Disease Control and 
Prevention (CDC) will publish periodic summaries of proposed projects. 
To request more information on the proposed projects or to obtain a 
copy of the data collection plans and instruments, call 404-639-7570 
and send comments to Ron Otten, at CDC 1600 Clifton Road, MS-D74, 
Atlanta, GA 30333 or send an email to [email protected].
    Comments are invited on: (a) Whether the proposed collection of 
information is necessary for the proper performance of the functions of 
the agency, including whether the information shall have practical 
utility; (b) the accuracy of the agency's estimate of the burden of the 
proposed collection of information; (c) ways to enhance the quality, 
utility, and clarity of the information to be collected; and (d) ways 
to minimize the burden of the collection of information on respondents, 
including through the use of automated collection techniques or other 
forms of information technology. Written comments should be received 
within 60 days of this notice.

Proposed Project

    Risk Factors for Invasive Methicillin-resistant Staphylococcus 
aureus (MRSA) among Patients Recently Discharged from Acute Care 
Hospitals through the Active Bacterial Core Surveillance for Invasive 
MRSA infections (ABCs MRSA)--NEW--National Center for Emerging and 
Zoonotic Infectious Diseases (NCEZID), Centers for Disease Control and 
Prevention (CDC).

Background and Brief Description

    Preventing healthcare-associated invasive MRSA infections is one of 
CDC's priorities. The goal of this project is to assess risk factors 
for invasive healthcare-associated MRSA infections, which will inform 
the development of targeted prevention measures. This activity supports 
the HHS Action Plan for elimination of healthcare-associated 
infections.
    Essential steps in reducing the occurrence of healthcare-associated 
invasive MRSA infections are to quantify the burden and to identify 
modifiable risk factors associated with invasive MRSA disease. CDC's 
current ABCs MRSA surveillance has been essential to quantify the 
burden of invasive MRSA in the United States. Through this 
surveillance, CDC was able to estimate that 94,360 invasive MRSA 
infections associated with 18,650 deaths occurred in the United States 
in 2005. The majority of these invasive infections (58%) had onset in 
the community or within three days of hospital admission and occurred 
among individuals with recent healthcare exposures (healthcare-
associated community-onset [HACO]). More recent data from the CDC's 
ABCs MRSA system have shown that two-thirds of invasive HACO MRSA 
infections occur among persons who are discharged from an acute care 
hospital in the prior three months. Risk factors for invasive MRSA 
infections post-discharge have not been well evaluated, and effective 
prevention measures in this population remain uncertain.
    For this project, an estimated total of 450 patients (150 patients 
with HACO MRSA infection post-acute care discharge and 300 patients 
without HACO MRSA infection) will be contacted for the MRSA interview 
annually. This estimate is based on the numbers of MRSA cases reported 
by the ABCs MRSA sites annually (http://www.cdc.gov/abcs/reports-findings/survreports/mrsa08.html) who are 18 years of age or older, had 
onset of the MRSA infection in the community or within three days of 
hospital admission, and history of hospitalization in the prior three 
months. ABCs MRSA surveillance case report forms will be used to 
identify HACO MRSA cases to be contacted for a telephone interview. For 
each HACO MRSA case identified; two patients without HACO MRSA 
infection (control-patients) matched on age with MRSA case will be 
contacted for a health interview. All 450 patients (both cases and 
controls) will be screened for eligibility and those considered to be 
eligible will complete the telephone interview. We anticipate that 350 
of the 450 patients screened will complete the telephone interview 
across all six participating ABCs MRSA sites per year. We anticipate 
the screening questions to take about 5 minutes and the telephone 
interview 20 minutes per respondent.
    There are no costs to respondents. The total response burden for 
the study is estimated as follows:

 
----------------------------------------------------------------------------------------------------------------
                                                                     Number of    Average burden
      Type of respondents           Form name        Number of     responses per   per response    Total burden
                                                    respondents     respondent      (in hours)      (in hours)
----------------------------------------------------------------------------------------------------------------
Hospital Patients.............  Screening Form..             450               1            5/60              38
                                Telephone                    350               1           20/60             117
                                 interview.
                                                 ---------------------------------------------------------------
    Total.....................  ................  ..............  ..............  ..............             155
----------------------------------------------------------------------------------------------------------------



[[Page 24210]]

    Dated: April 17, 2012.
Ron A. Otten,
Director, Office of Scientific Integrity, Office of the Associate 
Director for Science (OADS), Office of the Director, Centers for 
Disease Control and Prevention.
[FR Doc. 2012-9720 Filed 4-20-12; 8:45 am]
BILLING CODE 4163-18-P